A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18INK4C Expression in Advanced Breast Carcinoma
Modern Pathology · 2025
DOI: 10.1016/j.modpat.2025.100841 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2025. Verfasst von Xiao Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama; Now with Department of Anatomical Pathology, The University of…. Hauptthemen laut MEDLINE: GATA3 Transcription Factor, Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: University of Alabama.
Abstract (Originalsprache)
Cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) with endocrine therapy benefits patients with hormone receptor-positive, human epidermal growth receptor 2-negative breast carcinomas. However, most tumors develop resistance to CDK4/6i during the course of therapy. Although preclinical studies have proposed molecular mechanisms for the resistance, predictive markers are yet to be discovered. We investigated the tumor molecular profiling in 42 patients with advanced-stage breast carcinoma who received CDK4/6i therapy. The tumors carrying a GATA-binding protein 3 (GATA3) gene mutation, mainly a frameshift variant, showed a better treatment response compared with other tumors. Furthermore, we explored the potential underlying mechanism of this association. To that end, nuclear expression of p18, one of the INK family proteins, was found to be positively associated with the GATA3 mutation, as well as a CDK4/6i treatment response. Therefore, our study suggests that a GATA3 gene mutation, collaborating with p18 protein expression in tumor nuclei, may have a predictive value for CDK4/6i therapy in breast carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama; Now with Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:…
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama.
- Breast Medical Oncology Section, Division of Hematology & Oncology, The University of Alabama at Birmingham, Birmingham, Alabama.
- Department of Radiology, The University of Alabama at Birmingham, Birmingham, Alabama.
Förderung
- University of Alabama
Zitieren
APA
Huang, X., Varambally, S., Anderson, S. A., Bartow, B. B., Harada, S., Wei, S., Siegal, G. P., Khoury, K., & Yalniz, C. (2025). A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18INK4C Expression in Advanced Breast Carcinoma. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100841
Vancouver
Huang X, Varambally S, Anderson SA, Bartow BB, Harada S, Wei S, et al. A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18INK4C Expression in Advanced Breast Carcinoma. Modern Pathology. 2025. doi:10.1016/j.modpat.2025.100841
BibTeX
@article{Huang2025,
author = {Huang, Xiao and Varambally, Sooryanarayana and Anderson, Sarah A and Bartow, Brooke B and Harada, Shuko and Wei, Shi and Siegal, Gene P and Khoury, Katia and Yalniz, Ceren},
title = {A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18INK4C Expression in Advanced Breast Carcinoma},
journal = {Modern Pathology},
year = {2025},
doi = {10.1016/j.modpat.2025.100841}
}
EUVIMED